Keryx Biopharmaceuticals (KERX US)

Keryx Biopharmaceuticals, Inc. is focused on developing and commercializing pharmaceuticals for the treatment of renal disease. The Company's product candidate completed Phase 3 testing, pursuant to an SPA agreement with the FDA, for hyperphosphatemia in ESRD patients. The product candidate is also in Phase 2 for non-dialysis dependent CKD patients with iron-deficiency anemia.